Phase III, randomized, open-label study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC): Findings from an interim safety analysis
暂无分享,去创建一个
T. Conroy | M. Ychou | M. Ducreux | J. Douillard | M. Hebbar | A. Adenis | J. Bennouna | G. Lledo | R. Faroux | B. Paillot